Data retrieval using the new SMQ Medication Errors

Similar documents
Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

MedDRA Coding Quality: How to Avoid Common Pitfalls

MedDRA Basic Concept

Frequently Asked Questions

GDUFA: 2 ½ years later Impact & Importance

Global Pediatric Development: We Are Making Progress. PMDA Perspective. Junko Sato, PhD PMDA

Other EU Activities Contributing to Harmonization of Labeling

MedDRA Overview A Standardized Terminology

Use of MedDRA in Special Situations

Session 2. Data analysis based on overview of EudraVigilance data. Victoria Newbould, EMA, EU. Medication-errors workshop London, 20 October 2016

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Medication Errors a challenge of pharmacovigilance BfArM experience

9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience

Healthcare Professional Information & Patient Information Leaflet (PL)

Regulatory scientific significance of Japan s ADR relief system

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

Web-based epro: Validation, Equivalence, and Data Quality. Brian Tiplady

Disclaimer. Statistical Aspects of Revision of CHMP Bioequivalence Guidelines. David Brown MHRA

What s New MedDRA Version March

PMDA Perspectives on Oncology Panel. REIKO YANAGIHARA, Ph.D. Office of In Vitro Diagnostics PMDA

MedDRA Coding and Versioning

MedDRA Term Selection: Latest activities of the Points to Consider Working Group

Regulatory Experience in Reviewing CV Safety for Diabetes

So, My FitBit is Clinical Trial Grade Right? Keith Wenzel Senior Director, Solution Incubator PAREXEL International

Disclaimer. Dialogue with a Patient 3/18/2016

Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be

Advanced MedDRA Coding

Safety Data Analysis and Query Creation with MedDRA

Centralized Procedure

Conducting Observational studies in Latin America: Academia, Ethical Committees & Pharmaceutic Industry

Data Analysis and Query Building with MedDRA

Existing WHO work on Medicines Safety & Safe Use. Department of Essential Medicines and Health Products World Health Organization

What s New MedDRA Version 13.1

What s New MedDRA Version 18.0

Medication errors. Impact of medication error guidance and regulation on drug-device combination products. June 2017 Dan Wozinski

What s New MedDRA Version MSSO-DI March 2016

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes

The Adverse Reactions and Interactions

Food can serve as a non pharmacological control in thorough cardiac safety studies

PHARMACOVIGILANCE GLOSSARY

REPUBLIC OF KENYA MINISTRY OF MEDICAL SERVICES PHARMACY AND POISONS BOARD

PIP Modifications Workshop. Co-Chairs

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS

How to change the legal classification of a medicine in New Zealand

Life-cycle approach to error prevention an overview

3/31/2009. Phase 0 Microdosing Studies with Renin Inhibitors. Disclaimer. Overview of Today s Presentation. J. Chris Jensen Consultant

Introduction to MedDRA

The Telemetric and Holter ECG Warehouse (THEW) Initiative

10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer

What s New MedDRA Version March

Q&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015

ANSM (France) Inspections in both materiovigilance and pharmacovigilance.

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

WHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania.

Practice Direction Standard of Practice # 5: Administration of Drugs including Vaccines

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

Data Analysis and Query Building with MedDRA

Considerations for requiring subjects to provide a response to electronic patient-reported outcome instruments

Clinical Review Report (Sample)

Workshop Medication Errors

Comments received from public consultation on good pharmacovigilance practices (GVP)

Electrocardiographic Markers Associated with Sotalol-induced Torsades de Pointes

Frequently asked questions

6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia

Routine signal detection and statistical tools on paediatrics

Changing practice to support service delivery

DIA Oligonucleotide-Based Therapeutics Conference

Reflection paper on assessment of cardiovascular safety profile of medicinal products

Nova Scotia Drug Information System

ICD-10 Readiness (*9/14/15) By PracticeHwy.com, Inc.

Trademark Use Guidelines for Certified Products and Related Advertising

CHE8000 Major Research Project A. The Complementary Medicines Reforms and Its Impact to the Complementary Medicine Industry and the Consumer

What Medical Writers Need to Know About MedDRA

EMBASE Find quick, relevant answers to your biomedical questions

The European Medicines Agency (EMA)

Regulatory Aspects - AML & CLL

The Spreading Plague of Counterfeiting

The European Medicines Agency (EMA)

Meta-analysis of safety thoughts from CIOMS X

DATE: 17 July 2012 CONTEXT AND POLICY ISSUES

2016 EFPIA Data Collection and Reporting Experience - Novo Nordisk A/S learnings

Pharmacovigilance Methods and Post-Authorisation Safety Studies

We get your personal data from the following sources (examples detailed below are not exhaustive):

Guideline on good pharmacovigilance practices (GVP)

Switzerland - still a special country?

TRAUMA RECOVERY/HAP OPERATING GUIDELINES

Bioequivalence Requirements: USA and EU

MedDRA: Safety Data Analysis and SMQs

Blanka Hirschlerová. EDQM CEP conference Prague, Czech Republic

MedDRA Safety Data Analysis and SMQs

Clinical Trials in Third Countries

USE OF UNLICENSED MEDICINES AND OFF-LABEL MEDICINES WHERE A LICENSED MEDICINE IS AVAILABLE

January To: All Local CRN CHAPTERS

Summary of Changes to MedDRA TERM SELECTION: POINTS TO CONSIDER

European Medicines Agency decision

Cutanea Life Sciences, Inc. Comprehensive Compliance Program

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know

European Medicines Agency decision

What s New MedDRA Version 14.0

Transcription:

Data retrieval using the new SMQ Medication Errors Christina Winter Medical Director Safety Evaluation and Risk Management, GSK Information Day on Medication Errors 20 October 2016 London, UK

Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organisation with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. 2

Outline Background of SMQs What is the Medication Errors SMQ (SMQ ME)? Definition / Inclusion / Exclusion criteria Advantages/ Limitations of SMQ ME How to use SMQ ME Possible applications Data query (in post marketing database) Signal detection Risk management: frequency monitoring Automated alerts Periodic safety reporting (e.g. PBRERs, RMPs) 3

Background: Standardised MedDRA Queries (SMQs) Created to standardise identification and retrieval of safety data. Joint effort of Council for International Organizations of Medical Sciences (CIOMS) and ICH (including MSSO and JMO) Representing industry and regulatory authorities. SMQ is a grouping of terms from one or more SOCs related to condition of interest signs, symptoms, diagnoses, syndromes, physical findings, laboratory and other physiologic test data associated with the condition of interest. 4

What is the Medication errors SMQ? SMQ must match MedDRA version of dataset Refer to appropriate MSSO Introductory guide to SMQs Updated for MedDRA Versions 5

Introductory guide to SMQs 6

Medication errors (MEs) Definition (from SMQ Introductory guide) Any preventable events that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient or consumer. Definition (from EMA GPG*) A medication error is an unintended failure in the drug treatment process that leads to, or has the potential to lead to, harm to the patient. *Good practice guide on recording, coding, reporting and assessment of medication errors EMA/762563/2014 7

Medication errors (2) Types of MEs* (classification**) Result in an adverse drug reaction (Error with ADR) No clinical consequences (Error without harm) Intercepted prior to patient exposure (Intercepted error) Circumstances /information that may lead to ME (Potential error) *Introductory guide to SMQs ** EMA GPG 8

Inclusion criteria Narrow scope PTs refer to a ME according to the definition Broad scope PTs do not specifically represent a ME but have significant potential to identify ME (due to frequent association with MEs) E.g. product label issue terms, product exposure terms, and terms referring to administration of contraindicated drugs or other unapproved uses 9

Exclusion criteria (1) Intentional/deliberate use terms: by definition these are not medication errors Product contamination terms Transmission of infectious agent terms Off label use terms Drug interaction terms Counterfeit product terms 10

Exclusion criteria (2) Drug incompatibility terms Exposure terms that do not refer to product or drug exposure such as PT Exposure to body fluid Terms for non-specific and broad concepts that might produce substantial noise in data retrieval, e.g., PT Device issue, PT Product quality issue, PT Poisoning, PT Treatment noncompliance 11

Advantages / Limitations of SMQ ME Advantages of using SMQ ME Standardised regulatory agencies and industry use common search criteria Maintained by MSSO (for MedDRA versions) Limitations Difficulties in coding (found during SMQ development) affect PT inclusion SMQs evolve Modifications for MedDRA versions Included PTs may change as coding improves (users becoming more accustomed to and selecting more specific ME terms) 12

Difficulties in coding: examples (1) Draft SMQ tested in 4 databases (3 regulators & 1 industry) Failure of child resistant mechanism for pharmaceutical product. Accidental ingestion not coded. Two cases: low noise level. Narrow PT. Device infusion issue, Product expiration date issue. Moderate number of cases, some MEs. Broad PTs. Device difficult to use. >1000 cases. Mostly product complaints but may be used to code MEs. Broad PT 13

Difficulties in coding: examples (2) Overdose >1000 cases. Some were accidental overdoses (miscoding). Broad PT Product quality issue. >2000 cases: few were ME. High noise level. PT excluded Off label use >7000 cases. Few co-reported terms that were MEs. Too noisy. PT excluded Intentional product misuse >13,000 cases. Very few ME. Too noisy. PT excluded 14

Coping with limitations Consider whether the dataset has common coding errors Conduct SMQ search first? Conduct supplementary search for PTs known to be common coding errors? SMQs change with MedDRA versions Document version number so that current SMQ content can be compared against future versions of this SMQ Possible future revision of SMQ ME to remove noisy terms (currently included to retrieve inaccurately coded cases) Document version number of SMQ for each search 15

SMQ ME v19.1 89 Narrow & 41 Broad PTs 16

How to use SMQ ME Obtain Introductory guide to SMQs (same MedDRA version as dataset) Review definition/inclusion/exclusion criteria Chose narrow or broad search. Narrow (scope) search includes narrow PTs Broad (scope) search includes narrow and broad PTs Run the appropriate search If SMQ not automated in database, appropriate PTs may be copied from MedDRA browser or SMQ excel spreadsheet from MSSO Manual review of the search output 17

Possible applications of SMQ ME (1) Data query In postmarketing database (as described in previous slide) Clinical trials: Errors may be recorded as protocol violations instead of ME. Check protocol violations as well as use of SMQ ME. Signal detection Signal detection often uses PTs but may apply any MedDRA hierarchical level. SMQs can also be utilised in some signal detection tools. 18

Possible applications of SMQ ME (2) Risk management: frequency monitoring Potentially useful tool to monitor the reporting rate of MEs Standardised set of terms Maintained for MedDRA versions Automated alerts Retrieve cases coded with any of the SMQ ME PTs for medical review and follow up Periodic safety reporting (e.g. PBRERs, RMPs) Consistent retrieval of ME cases for assessment and reporting 19

What SMQ ME will not do Data retrieved with SMQ ME requires manual review Accurate coding at data entry could reduce effort required to review search output SMQ ME cannot fully classify retrieved cases into categories required by EU* No codes for Error with ADR and Error without harm *Good practice guide on recording, coding, reporting and assessment of medication errors EMA/762563/2014 20

Summary Check MedDRA version Read relevant section of Introductory guide to SMQs Determine appropriate search scope (narrow or broad) Consider strategy for common miscoded cases (if relevant) Review search output manually 21

References (1) MSSO website http://www.meddra.org/how-to-use/support-documentation Look for MedDRA version-specific copies of Introductory guide to Standardised MedDRA Queries ICH MedDRA Data Retrieval and Presentation: Points to Consider. [See section 4, Standardised MedDRA Queries]

References (2) Council for International Organization of Medical Sciences (CIOMS) publication Development and Rational use of Standardised MedDRA Queries (SMQs): Retrieving Adverse Drug Reactions with MedDRA 2 nd Edition. 2016 Available at http://www.cioms.ch/index.php/pu blications/order-formv3 23

Ask